A new Cambridge startup has raised $28.5 million to revisit decades-old science in the hopes of treating diseases like multiple sclerosis.

Comet Therapeutics closed its Series A round this week, raising money from Canaan, Sofinnova Partners, and Cambridge’s BioInnovation Capital to help it get off the ground.

The startup is being led by former Syntimmune chief executive David de Graaf, who left the Waltham company shortly before it was purchased by Alexion Pharmaceuticals Inc. (Nasdaq: ALXN)…

Boston Biz Journal https://www.bizjournals.com/boston/news/2019/06/19/comet-launches-with-28m-to-turn-nobel-prize.html?ana=RSS&s=article_search